A Maharshi Dayanand University (MDU) researcher has designed an Anti Covid19 Vaccine. According to a report published, Dr Renu Jakhar who recently finished her Ph.D at centre for Medical Biotechnology of MDU Rohtak University, designed 3CL Hydrolase-based Multi-Epitope Peptide Vaccine on SARS-CoV-2. The said research paper of the Rohtak university researcher has been accepted for publication by the Journal of Medical Virology, a reputed international journal published from the United State of America, after sharing it with the World Health Organisation (WHO).
On Monday it is published that Rohtak university researcher has designed anti-Covid vaccine and has marked a major breakthrough. The ‘3CL Hydrolase-based Multi-Epitope Peptide Vaccine against SARS-CoV-2’ is designed by Dr Renu Jakhar with the help of eminent Scientist Prof SK Gakhar who is Vice Chancellor of Indira Gandhi University, Meerpur Rewari.
About the designed anti-Covid vaccine it is being said that the MDU Rohtak researcher designed is a protein-based vaccine which will strengthen our body’s immunity by raising the generation of antibodies against SARS-CoV-2. Utmost care has been taken to ensure that the epitopes used in the vaccine are non-toxic and non-allergic, Dr Renu said while talking to a English daily. Dr Renu Jakhar recently completed her PhD at Centre for Medical Biotechnology of MDU, by using immuno-informatics.
The researcher maintained that after the vaccine is ready, animal trials could be carried out at MDU if the government and university authorities grant permission to do so. It may be pertinent to mention here that the clinical trials on animals and human beings is a time-consuming process and it may take several months for the vaccine to be available in the market. The development of vaccines usually takes several years. It would be unprecedented if the vaccine is available by the end of the current year or early next year.
SK Gakhar is an eminent scientist and Vice-Chancellor of Indira Gandhi University (IGU), Meerpur, Rewari, under whose supervision the said research has been carried out, report said. This has become possible with the advent of computer-aided immuno-informatics tools, genetic and protein engineering, observes Prof SK Gakhar.
Source- The Tribune